Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bwaaaaaaaaaaaaa.
Because they don’t get it. It’s simple really. If what they say is looking good comes to fruition this will be f- - - - ing HUGE!!! If not. It’s gonna suck. That simple. I must say though why so many derogatory insults and some for sure false claims are continuously be posted here. By folks who claim it’s all a scam and they own no shares ask yourself. Over 3100 posts for a stock one doesn’t care about. Things that make go Hmmmm!! Bottom line if they succeed in their ventures it’s a winner. If not. NEXT!!
Interesting
The Company and the Plaintiff mutually agreed to dismiss all claims other than the Company’s claims against the Plaintiff in the USA.
Me either
Relentless
Omg. So you are calling them all liars. Oh boy
Omg. Relentless
Yeah. You know the glow is gonna spin the shit outta this one. Hahaha
But. But. But. You said the s-1 wouldn’t. Couldn’t. Be approved because of the investigation. It was approved. So tell us glow. Which one is it
Omg. Same stuff. Over and over and over over over and over and over over again again and over over again and over again again and over over again and over again again and over over again and over again again and over over again and over again again and over over over over again and over over again again and over over again and over again. Whew!!!
Why do you care
Where’s the F. B. Page. Seems to be no longer there
Realistically no one here knows that they don’t have their act incredibly together as we sit. I like to think they know exactly what they are doing
Have seen zero proof of anything you said Please show proof
I send a lot of copied emails from here to OWC. So they are aware of the probable slander going on. Seems strange non the less why people would post so much when they state how this sucks so bad. Things that make you go hmmmmm
So. Who can prove crab ?? wrong. If he’s correct then all those Doctors etc are nothing but scammers. Really? Wtf. Real answers would be nice. And I was in Florida and spoke with Hirsch I certainly hope crab is full of it.
Dr. Stanley HirschChairman of the BoardStanley Hirsch, D.Phil., has been a member of the company’s board of directors since 2005, and has served as Chairman of the board of Foamix since May, 2016. Dr. Hirsch has 30 years of experience in executive positions across the healthcare, diagnostic, and agricultural/biotech industries. He has extensive executive and board level experience in public and private companies listed on both U.S and U.K exchanges. Dr. Hirsch is currently Group CEO at FuturaGene Ltd., a leading agricultural biotechnology company, where he has held this position since 2007. Prior to this role, Dr. Hirsch was the CEO at CBD Technologies Ltd., the predecessor company to FuturaGene, from 1995 until 2007. Prior executive positions held by Dr. Hirsch include CEO at a diagnostics company GamidaGen, and General Manager at Portman Pharmaceuticals. Dr. Hirsch currently also serves as Chairman of the board of directors of OWC Pharmaceutical Research Corporation (OWCP), and as a board director and member of the Scientific Advisory Board of Biological Industries, a privately held research products company focused on the stem cell industry. Dr. Hirsch holds a D. Phil in Cell Biology and Immunology from Oxford University, England.
Yup. No selling either
Log In
Sign Up
Find a Lawyer Ask a Lawyer Research the Law Law Schools Laws & Regs Newsletters Legal Marketing
Justia Patents Oron Yacoby-Zeevi Inventions, Patents and Patent Applications
Patents by Inventor Oron Yacoby-Zeevi
Oron Yacoby-Zeevi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Dopa decarboxylase inhibitor compositions
Patent number: 10022320
Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
Type: Grant
Filed: March 12, 2015
Date of Patent: July 17, 2018
Assignee: NeuroDerm, Ltd.
Inventor: Oron Yacoby-Zeevi
Compositions comprising apomorphine and organic acids and uses thereof
Patent number: 9999674
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Grant
Filed: June 5, 2013
Date of Patent: June 19, 2018
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9993451
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: July 1, 2015
Date of Patent: June 12, 2018
Assignee: NeuroDerm, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
OPIPRAMOL PATCH
Publication number: 20180140610
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of active agents such as opipramol. More particularly, the disclosed transdermal compositions include an active agent; one or more plasticizers; one or more penetration enhancers; a pressure-sensitive adhesive; and may include one or more hydrophilic polymers.
Type: Application
Filed: September 18, 2015
Publication date: May 24, 2018
Applicant: NeuroDerm, Ltd.
Inventors: Oron YACOBY-ZEEVI, Mara NEMAS
CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF
Publication number: 20170368052
Abstract: The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms such as acid addition salts of apomorphine, because of their increased/greater stability and/or improved pharmacological properties, e.g., decreased adverse reactions at the site of administration. The invention further provides liquid formulations obtained by dissolving said crystalline forms of apomorphine in a solvent, as well as a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, or a condition associated therewith, by administration of said liquid formulations.
Type: Application
Filed: December 23, 2015
Publication date: December 28, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Jonathan Cummins, Petra Dieterich
PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA AMIDE AND USES THEREOF
Publication number: 20170296491
Abstract: The present invention discloses various aqueous pharmaceutical compositions comprising a levodopa amide compound, or a salt thereof, which are stable for at least 24 hours at room temperature, and use thereof in treatment of diseases or disorders characterized by neurodegeneration and/or reduced levels of brain dopamine, e.g., Parkinson's disease.
Type: Application
Filed: November 23, 2016
Publication date: October 19, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik, Irena Vainshtok, Einat Sela
Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20170196828
Abstract: Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof.
Type: Application
Filed: August 23, 2016
Publication date: July 13, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas
DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS
Publication number: 20170157079
Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
Type: Application
Filed: February 21, 2017
Publication date: June 8, 2017
Inventor: Oron Yacoby-Zeevi
CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME
Publication number: 20170157077
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: July 13, 2016
Publication date: June 8, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas
COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS
Publication number: 20170157076
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
Type: Application
Filed: July 8, 2016
Publication date: June 8, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik
Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
Patent number: 9421267
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Grant
Filed: November 15, 2011
Date of Patent: August 23, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
Compositions for transdermal delivery of active agents
Patent number: 9415108
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
Type: Grant
Filed: November 15, 2011
Date of Patent: August 16, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik
Compositions comprising apomorphine and organic acids and uses thereof
Patent number: 9381249
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly compositions comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Grant
Filed: November 18, 2015
Date of Patent: July 5, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20160151317
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: July 1, 2015
Publication date: June 2, 2016
Inventors: Oron Yacoby-Zeevi, Mara Nemas
COMPOSITIONS COMPRISING APOMORPHINE AND ORGANIC ACIDS AND USES THEREOF
Publication number: 20160067339
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly compositions comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Application
Filed: November 18, 2015
Publication date: March 10, 2016
Inventors: Oron Yacoby-Zeevi, Mara Nemas
METHOD FOR TREATMENT OF PARKINSON'S DISEASE
Publication number: 20160022573
Abstract: The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.
Type: Application
Filed: March 13, 2014
Publication date: January 28, 2016
Applicant: NEURODERM, LTD.
Inventor: Oron Yacoby-Zeevi
DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS
Publication number: 20150352212
Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
Type: Application
Filed: March 12, 2015
Publication date: December 10, 2015
Inventor: Oron Yacoby-Zeevi
Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9101663
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: December 7, 2010
Date of Patent: August 11, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
COMPOSITIONS COMPRISING APOMORPHINE AND ORGANIC ACIDS AND USES THEREOF
Publication number: 20150182523
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Application
Filed: June 5, 2013
Publication date: July 2, 2015
Inventors: Oron Yacoby-Zeevi, Mara Nemas
Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9040589
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 13, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
1 2 3 next
Ask a Lawyer
Question:
Add details
120
Ask Question
Find a Lawyer
Lawyers - Get Listed Now!
Get a free directory profile listing
Justia Legal Resources
Find a Lawyer
Bankruptcy Lawyers
Business Lawyers
Criminal Lawyers
Employment Lawyers
Estate Planning Lawyers
Family Lawyers
Personal Injury Lawyers
More...
Individuals
Bankruptcy
Criminal
Divorce
DUI
Estate Planning
Family Law
Personal Injury
More...
Business
Business Formation
Business Operations
Employment
Intellectual Property
International Trade
Real Estate
Tax Law
More...
Law Students
Law Schools
Admissions
Financial Aid
Course Outlines
Law Journals
Blogs
Employment
More...
US Federal Law
US Constitution
US Code
Regulations
Supreme Court
Circuit Courts
District Courts
Dockets & Filings
More...
US State Law
State Constitutions
State Codes
State Case Law
California
Florida
New York
Texas
More...
Other Databases
Legal Blogs
Legal Forms
GAO Reports
Product Recalls
Patents
Trademarks
Countries
More...
Legal Marketing
Law Firm Websites
Lawyer Blogs
Content
Social Media
Local Marketing
Paid Ads (CPC/PPC)
Lawyer Directory
More...
© 2018 Justia
Legal Portal Company Help Terms of Service Privacy Policy Marketing Solutions
Was that before or after they approved the s-1. Come on will u
Let’s get this thing Glowing over here. Lol. Boom
Man your like a watt that won’t go away. Same old nonsense come up with something new
In the otc they are not required to execute. Hence all the manipulation. IMO
They do not answer my emails that’s for sure
Good lord. All hear say by u. Prove it
Baseless information you say the things you say because you haven’t seen the results yet from the company that I guess you have expected and many others time will tell
Smartest guy in the room. Ask him
What letter. Where’s the info
lol. I don’t get that one.
Lol. Where oh where do you see that fact. Boy
Lol. Where is that stated. Over 6.7 is accounted for. U r funny
I do not believe the 8 ks are all lies as you do. And you have zero proof but soon we will see. Hope your very very incorrect. Owcp
That is a lie. $6,737,000.00 plus is accounted for. Look at the release. 1.8. 687. 350. 100. 300 plus. 500 and 3.0 mil. Keep it clean glow
Why doesn’t one world cannabis show up when I do a search on Edgar thank you
Show us your dorm room DD then. Thanks
I think you might need to listen again Dr. Hirsch said we have funding through 2018 and then they are clearly thinking ahead for other funding Beyond that that will clearly differentiate themselves . 2018 is done. People need to read between the lines good luck to all. Owcp!!
Hard to dispute. But they will.
Because he thought no one would notice seeing owc trades like they do. And to use the funds for his credit card bills and all the other crap he bought. Lol
Yes it is. Same train.